The Lynx Group

Bosutinib NDA Accepted for CML

February 2012, Vol 3, No 1

The FDA has accepted a New Drug Application (NDA) for bosutinib (Pfizer), an oral dual Src and Abl tyrosine kinase inhibitor, as a second-line therapy for adult patients with previously treated Philadelphia chromosome–positive (Ph+) chronic myeloid leukemia (CML).

The submission was based on efficacy and safety data from a single-arm study of bosutinib in more than 500 patients with previously treated Ph+ CML, including those who were resistant or intolerant to imatinib or had previously received dasatinib or nilotinib. (January 27, 2012)

Related Articles

Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive: